Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150

<p>Introduction: IMbrave150 established first-line atezolizumab plus bevacizumab as a global standard of care for unresectable hepatocellular carcinoma (HCC). We report exploratory analyses of associations between overall survival (OS) and depth of response (DpR) or duration of response (...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Masatoshi Kudo, Tatsuya Yamashita, Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Kaoru Tsuchiya, Naoya Sakamoto, Shuhei Hige, Ryosuke Take, Kyoko Yamada, Yuki Nakagawa, Hayato Takahashi, Masafumi Ikeda
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Karger Publishers 2025-01-01
Saila:	Liver Cancer
Sarrera elektronikoa:	https://karger.com/article/doi/10.1159/000544981
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!